Marker Therapeutics Inc

Marker Therapeutics operates with a strong liquidity position, as evidenced by a current ratio of 6.12 and cash and equivalents of $11.32 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The price-to-book ratio of 2.07 suggests that the market values the company at a premium to its book value, although this is not uncommon for biotechnology firms with high R&D investment.

The company is currently unprofitable, with a net loss of $2.39 million and an operating loss of $2.55 million in the latest period. Return on equity is negative at -20.3%, and return on assets is also negative at -16.98%, indicating that the company is not generating returns on its equity or asset base. These metrics are below the typical performance of the biotechnology industry, which often experiences early-stage losses before commercialization.

Marker Therapeutics does not disclose segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure. The company's revenue for the latest period was $1.24 million, which is relatively low, suggesting that it is in the early stages of commercialization or clinical development.

The company's growth trajectory is not clearly defined in the available data, as there is no prior revenue history provided for comparison. However, the company's current market cap of $24.34 million and the analyst price targets ranging from $5.60 to $10.00 suggest that there is some optimism about its future potential. The mean price target of $7.87 implies a potential upside of over 400% from the current market price of $1.46.

The risk assessment indicates that there are no immediate liquidity or dilution flags, and the company's dilution risk is rated as low. The company has not issued additional shares recently, and there is no indication of a pending equity offering or other dilutive event. The absence of long-term debt and the high cash balance further reduce financial risk.

There are no recent filings or transcripts provided in the available data to indicate any material events or developments at Marker Therapeutics. The company's financial performance and strategic direction would need to be evaluated in the context of its clinical pipeline and regulatory progress, which are not detailed in the current dataset.

Analysts project 509.8% upside to a mean price target of $7.87, signaling strong institutional confidence in future growth.

Revenue grew at a 27.8% CAGR over four years, demonstrating consistent top-line expansion despite ongoing operational losses.

The company maintains zero long-term debt, providing financial flexibility and eliminating interest expense burdens during development phases.

Operating and net margins exceed cohort medians, indicating relatively better cost efficiency compared to 372 biotechnology peers.

A current ratio of 8.39 suggests strong short-term liquidity, reducing immediate solvency risks for ongoing operations.

The company faces high credit risk, potentially limiting access to favorable financing terms for future capital requirements.

Net income deteriorated to -$12.2 million in FY2026, reflecting widening losses despite recent revenue growth trends.

Revenue declined 6.6% year-over-year in the latest period, signaling potential stagnation or contraction in commercial traction.

Negative free cash flow of -$21.9 million in FY2023 highlights significant cash burn requiring continuous external funding.

Revenue $1.1M, −51,0% YoY; Operating income +51,2% YoY.

• ▍Revenue $1.1M, −51,0% YoY
• ▍Operating income +51,2% YoY
• ▍Net income +55,6% YoY
• ▍Net margin -154.4%

Revenue $1.2M, −36,0% YoY; Operating income +11,0% YoY.

• ▍Revenue $1.2M, −36,0% YoY
• ▍Operating income +11,0% YoY
• ▍Net income +13,4% YoY
• ▍Net margin -162.1%

Revenue $861.2k, −26,4% YoY; Operating income −84,6% YoY.

• ▍Revenue $861.2k, −26,4% YoY
• ▍Operating income −84,6% YoY
• ▍Net income −83,1% YoY
• ▍Net margin -466.3%

Revenue $349.1k, −71,9% YoY; Operating income −80,8% YoY.

• ▍Revenue $349.1k, −71,9% YoY
• ▍Operating income −80,8% YoY
• ▍Net income −85,8% YoY
• ▍Net margin -1273.6%

Revenue $2.3M; Operating income -$3.9M.

• ▍Revenue $2.3M
• ▍Operating income -$3.9M
• ▍Net margin -170.4%

Revenue $1.9M; Operating income -$2.4M.

• ▍Revenue $1.9M
• ▍Operating income -$2.4M
• ▍Net margin -119.8%

Revenue $1.2M; Operating income -$2.3M.

• ▍Revenue $1.2M
• ▍Operating income -$2.3M
• ▍Net margin -187.5%

Revenue $1.2M; Operating income -$2.5M.

• ▍Revenue $1.2M
• ▍Operating income -$2.5M
• ▍Net margin -192.3%

Revenue $3.5M, −46,2% YoY; Operating income −15,9% YoY.

• ▍Revenue $3.5M, −46,2% YoY
• ▍Operating income −15,9% YoY
• ▍Net income −13,3% YoY
• ▍Net margin -343.0%

Revenue $6.6M, +99,1% YoY; Operating income +23,8% YoY.

• ▍Revenue $6.6M, +99,1% YoY
• ▍Operating income +23,8% YoY
• ▍Net income −30,3% YoY
• ▍Net margin -162.8%

Revenue $3.5M, +183,0% YoY; Operating income +52,2% YoY.

• ▍Revenue $3.5M, +183,0% YoY
• ▍Operating income +52,2% YoY
• ▍Net income +28,5% YoY
• ▍Free cash flow +48,8% YoY
• ▍Net margin -851.9%

Revenue $1.2M; Operating income -$41.9M.

• ▍Revenue $1.2M
• ▍Operating income -$41.9M
• ▍Net margin -3372.7%